肺癌免疫查核点抑制剂市场：依癌症类型、通路、治疗方法、最终用户、作用机制和治疗线划分－全球预测（2025-2032年）

预计到 2032 年，肺癌免疫查核点抑制剂市场将成长至 35.5 亿美元，复合年增长率为 15.05%。

关键市场统计数据
基准年 2024	11.5亿美元
预计年份：2025年	13.2亿美元
预测年份 2032	35.5亿美元
复合年增长率 (%)	15.05%

透过概述临床进展、相关人员的优先事项和决策需求，为肺癌免疫查核点抑制剂的策略应用奠定基础。

免疫查核点抑制剂从根本上改变了肺癌的治疗模式，使治疗策略从单纯的细胞毒性疗法转向以靶向免疫调节为核心，旨在产生持久的临床疗效。在过去十年间，临床医生和研究人员不断加深对肿瘤-免疫相互作用的理解，并将这些发现转化为重新运作抗肿瘤免疫的疗法，从而显着改善了许多患者的生存期和生活品质。

本导言概述了相关人员在评估免疫查核点抑制剂项目时必须考虑的临床、营运和商业性方面。在临床方面，整合生物标记检测、优化患者选择以及优化与化疗和分子标靶药物的联合治疗仍然是治疗团队的关键考虑因素。在营运方面，生物製药引入的复杂性会影响医院和门诊的药物分发方案、低温运输物流以及输注能力规划。在商业性，与支付方达成一致、产生支持报销的证据以及基于作用机制和治疗线进行差异化定位是推广策略的核心。

接下来的分析综合了临床进展、监管态度和系统层面的压力，以提供对机会和风险的平衡视角，旨在为决策者提供清晰简洁的依据，以便优先考虑投资和伙伴关係，从而加速对患者产生有意义的影响。

识别肺癌免疫疗法转型中的转变，包括生物标记主导的治疗、联合治疗以及监管和支付方动态

肺癌免疫治疗领域正经历多重并行且互补的变革，这些变革正在改变治疗方法的研发、评估和实施方式。首先，临床实践正朝着精准免疫肿瘤学的方向发展，生物标记主导的选择，例如PD-L1表达和广泛的基因组特征，如今已体现在治疗方案的选择和临床试验的入组中。因此，试验设计越来越多地采用适应性队列和生物标记富集组，以提高讯号检测的准确性并加快监管决策。

第二，目前研发的重点是联合治疗透过将查核点抑制剂与化疗、分子标靶药物或其他免疫调节剂合併使用，以解决抗药性机制并增强疗效持久性。此类联合治疗需要新的安全管理模式和新的临床终点，这将影响监管机构的参与和支付方的证据预期。第三，监管机构和支付者越来越重视真实世界证据和卫生经济学结果，鼓励申办者在传统的随机试验之外，投资于纵向资料收集和结果研究。

第四，生产製造和供应链的考量正在推动可扩展生技药品生产和低温运输物流的投资。同时，数位医疗工具和分散式调查方法正在改善患者就医和留存率，并将潜在的研究对象扩展到传统学术中心之外。总而言之，这些转变正在创造一种环境，在这种环境中，临床策略、数据生成和相关人员参与方面的灵活性将决定哪些治疗方法能够被广泛采用并为患者带来切实的益处。

评估美国新关税政策对2025年肺癌免疫疗法供应链、临床计画和商业性准入的累积影响

影响跨境贸易的政策行动会对药物研发和商业化生态系统产生连锁反应，而提案的2025年关税调整方案为免疫查核点抑制剂计画带来了复杂的营运和经济考量。对进口生物製药、专用试剂和成品征收更高的关税可能会增加产品的单位成本，并迫使製造商重新评估筹资策略和製造外包关係。为此，申办方可能会加快供应链在地化进程，重新谈判长期供应商协议，或实现供应商多元化，以降低单一来源风险。

临床研发极易受到供应中断和成本波动的影响。关税上涨导致的临床供应成本增加以及海关延误会使临床试验物流变得复杂，尤其是在依赖药物同步运输的多中心试验中。申办者可以透过建立缓衝库存、认证多个仓库以及尽可能利用区域生产中心来降低这种风险。同时，随着支付方对价格上涨的审查日益严格，商业性准入策略也可能需要做出调整。

最后，政策环境可以鼓励策略伙伴关係和垂直整合，促使企业探索本地生产或授权安排，以保障利润率和供应安全。虽然关税会增加复杂性，但积极主动的产业计画、基于情境的财务建模以及与监管机构和海关当局的早期沟通可以减少中断，并保障患者获得关键免疫疗法的机会。

透过基于细分市场的洞察优化定位，包括癌症类型、分销管道、治疗方法、机制、治疗线和最终用户。

对肺癌细分的细緻理解对于针对不同肺癌谱系製定个人化的研发和商业化策略至关重要。在同一类肺癌中，非小细胞肺癌和小细胞肺癌之间的差异决定了不同的临床试验设计、监管终点和处方模式。在非小细胞肺癌中，非鳞状细胞癌和鳞状细胞癌的组织学差异会影响预期疗效和安全性。此外，在非鳞状细胞癌中，腺癌和大细胞癌等亚型可以预测生物标记的出现以及与标靶治疗的相互作用。

从医院药局到线上药局、零售药局和专科药房，分销管道的选择决定了物流模式、病患支援系统和报销途径。治疗方法分为单药治疗和联合治疗。当联合治疗包含化疗或标靶治疗时，临床开发策略必须考虑药物迭加毒性和治疗定序。终端使用者细分，例如门诊手术中心、家庭护理机构、医院和肿瘤诊所，会影响设施准备、输液能力和病患导航服务的设计。

某些药物，例如Ipilimumab、西米木单抗、Nivolumab、Pembrolizumab、Atezolizumab和Durvalumab，其临床特征对于药物标籤和市场定位至关重要。此外，一线、二线和三线或后续治疗方案之间的差异决定了取代现有药物竞争药物所需的证据标准。整合这些细分维度，有助于申办方优先考虑临床项目、通路策略和证据生成，以满足不同患者群体和医疗机构的需求。

美洲、欧洲、中东和非洲以及亚太地区的优先事项和差异化采取路径

临床实务、监管方式和医疗基础设施的区域差异显着影响免疫查核点抑制剂的推广和应用。在美洲，完善的医保报销机制、强大的肿瘤治疗网络和健全的临床试验能力支持新型疗法的快速应用，但成本控制和支付方对疗效的审查仍然是需要考虑的因素。该地区的打入市场策略通常结合可靠的III期临床试验证据和真实世界研究结果，以确保获得处方权和有利的用药政策。

欧洲、中东和非洲的法律规范和支付模式各不相同，因此需要采取细緻入微的方法，充分考虑各国卫生技术评估流程的差异、报销方案的不同以及物流能力的差异。与区域卫生部门和相关人员合作至关重要，这有助于使临床证据包与各国的具体价值框架相符。亚太地区的医疗保健体係也多种多样，既有已开发市场（其应用正在加速推进），也有新兴市场（其准入受限和基础设施不足，需要製定适应性强的分销和患者援助计划）。在亚太地区，在地化生产和策略伙伴关係对于提高医疗服务的可负担性和供应可靠性尤其有效。

在所有地区，如何使实证医学的产生与当地决策驱动因素相契合、如何加大对临床医生教育的投入以及如何设计灵活的分发模式都是核心挑战。跨区域合作能够充分发挥全球研发的效率，同时又能针对当地监管和支付方环境进行有针对性的调整。

竞争对手和合作伙伴层面的分析表明，创新、伙伴关係和产品组合策略将决定肺癌免疫疗法领域的领导地位。

各公司在肺癌免疫疗法领域的策略正围绕着几个主题：差异化的临床定位、策略联盟、产品组合的广度以及实证医学能力。优先发展强大的生物标记计画并与伴随诊断公司合作的公司，能够精准触及临床定义的、治疗获益最为显着的亚群患者。投资联合治疗并有效管理早期安全性讯号的公司，则能够与单药疗法形成显着的差异化优势。

从与生物技术创新者进行研究合作，到与标靶药物生产商达成共同开发契约，策略联盟得以加速获取互补疗法，并拓展抗药性疾病的临床治疗选择。那些在真实世界证据生成、卫生经济学和结果研究方面建立综合能力的公司，能够增强其与支付方的谈判筹码，并促进医保报销谈判。同时，对可扩展生技药品生产和地理分散的供应链进行投资，可以降低营运风险，并支持更可预测的商业化推广。

竞争优势还取决于商业性执行力，领导企业将提供全面的患者援助计划、治疗医师培训以及反映价值导向的灵活定价策略。那些将强大的临床数据、卓越的营运以及与支付方利益相符的提案主张相结合的公司，将更有利于在各种医疗环境中持续获得认可并长期应用。

为行业领导者提供可操作的建议，以加速免疫疗法开发、改善可及性并建立稳健的商业性和临床路径

产业领导者可以透过推行一系列切实可行的高优先倡议来加速发展并降低商业化风险。首先，将研发组合与生物标记定义的适应症相匹配，并儘早开发伴随诊断策略，从而简化监管流程并优化患者筛选。同时，设计包含适应性要素和以病人为中心的有意义终点的联合试验，以展现超越传统生存指标的价值。其次，投资于分散式和混合式试验模式，以产生更具代表性的真实世界证据，从而扩大应用范围、提高患者留存率并促进与支付方的对话。

第三，透过供应商多元化、区域化生产选择和库存策略来加强供应链，进而降低贸易中断和政策衝击带来的风险。第四，积极与支付方沟通，提供透明的价值文件和基于结果的合同，以解决支付方对医疗费用可及性的担忧，同时保障患者的医疗服务可及性。第五，建立差异化的患者援助计划，以提高患者的治疗依从性，管理免疫相关不利事件，并确保在医院、肿瘤诊所、家庭护理机构和专科药房之间实现医疗服务的连续性。

最后，与诊断公司、学术中心和受託研究机构建立策略伙伴关係，以加速转化科学和临床开发。透过实施这些建议，领导者可以提高产品成功上市、永续取得以及患者疗效显着改善的可能性。

透过严谨的调查方法，详细阐述证据来源、专家参与、三角验证技术以及局限性，从而打造引人注目的市场情报。

本报告的分析整合了多方面的证据，以确保结论严谨可靠。二次研究包括同行评审的临床文献、监管指导文件以及公开的临床试验註册库，旨在阐明治疗机制、安全性特征和试验设计。为补充这些资讯来源，我们还对肿瘤内科医生、临床试验研究人员、卫生经济学专家、监管事务专家和供应链负责人进行了结构化访谈，以收集经验见解和营运挑战。

资料三角测量法将定性访谈结果与已发表的证据联繫起来，以检验新出现的主题并识别公开记录中的空白。細項分析应用于临床、分销和最终用户维度，以揭示不同的采用路径。调查方法的局限性包括临床数据的快速变化、监管时间表的区域差异以及新试验结果可能改变竞争动态。

在适当情况下，调查方法优先考虑资讯来源选择和分析假设的透明度，使相关人员能够评估关键发现的来源，并调整方法以进行专注于特定地区、机製或治疗方法组合的客製化分析。

本文综合分析了临床创新、政策变革和营运重点等面向肺癌免疫治疗相关人员的策略意义。

科学创新、策略性商业化策略和不断变化的政策正在共同重塑免疫查核点抑制剂在肺癌治疗中的研发和应用方式。临床上，生物标记驱动的选择和联合治疗提高了治疗效果，同时也为安全性管理和试验设计带来了新的复杂性。在营运上，分销管道的选择和终端用户的接受程度会影响药物的可及性，而富有韧性的供应链对于在政策衝击下维持治疗的连续性至关重要。

从策略角度来看，整合诊断策略、投资可靠的真实世界证据项目并积极与支付方互动的公司将更有利于实现持续的市场推广。区域差异化需要量身订做证据方案和实施计划，以应对不同的监管和报销环境。综上所述，这些见解凸显了在临床开发、证据产生、生产製造和支付方互动等各个环节进行协调合作对于在该治疗领域取得成功的重要性。

最后，不断发展的免疫疗法领域为改善患者预后提供了重要的机会，但要实现这些益处，需要有条不紊的策略、营运韧性以及产业、临床医生和医疗保健系统之间的持续合作。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• FDA核准PD-1抑制剂辅助治疗早期非小细胞肺癌及其临床影响
• 一项真实世界研究凸显了查核点抑制剂在老年肺癌患者群体中的安全性
• 开发靶向PD-L1和LAG-3的下一代双特异性抗体治疗转移性肺肿瘤
• 整合液态生物检体生物标记预测非小细胞肺癌患者对免疫查核点抑制剂的反应
• 评估PD-1/PD-L1疗法在肺癌治疗中长期存活获益的新兴成本效益模型
• 扩大度Durvalumab单抗强化治疗在不可切除的III期非小细胞肺癌患者中放射线治疗后的适应症

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：肺癌免疫查核点抑制剂市场（依癌症类型划分）

• 癌症类型
  • 非小细胞肺癌
    • 非鳞状
    • 腺癌
    • 大细胞癌
    • 鳞状上皮
  • 小细胞肺癌

9. 肺癌免疫查核点抑制剂市场（依通路划分）

• 医院药房
• 网路药房
• 零售药房
• 专科药房

第十章：肺癌免疫查核点抑制剂市场（治疗方法）

• 联合治疗
  • 化疗
  • 标靶治疗
• 单药治疗

第十一章 肺癌免疫查核点抑制剂市场（依最终用户划分）

• 门诊手术中心
• 居家照护机构
• 医院
• 肿瘤诊所

第十二章：肺癌免疫查核点抑制剂市场（依作用机转划分）

• CTLA-4抑制剂
  • Ipilimumab
• PD-1抑制剂
  • 塞米普利单抗
  • Nivolumab
  • Pembrolizumab
• PD-L1抑制剂
  • Atezolizumab
  • Durvalumab

13. 肺癌免疫查核点抑制剂市场治疗线

• 第一排
• 第二行
• 从第三次开始

第十四章 肺癌免疫查核点抑制剂市场（按地区划分）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十五章 肺癌免疫查核点抑制剂市场（按组别划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十六章 各国肺癌免疫查核点抑制剂市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十七章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca PLC
  • Regeneron Pharmaceuticals, Inc.
  • Pfizer Inc.
  • BeiGene, Ltd.
  • Innovent Biologics, Inc.
  • Shanghai Junshi Biosciences Co., Ltd.
  • Sanofi SA

The Immune Checkpoint Inhibitors for Lung Cancer Market is projected to grow by USD 3.55 billion at a CAGR of 15.05% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 1.15 billion
Estimated Year [2025]	USD 1.32 billion
Forecast Year [2032]	USD 3.55 billion
CAGR (%)	15.05%

Setting the strategic context for immune checkpoint inhibitors in lung cancer by outlining clinical advances, stakeholder priorities, and decision-making imperatives

Immune checkpoint inhibitors have fundamentally altered the treatment paradigm for lung cancer, moving therapeutic strategy from cytotoxic-only approaches to targeted immune modulation that aims to deliver durable clinical benefit. Over the past decade, clinicians and researchers have advanced our understanding of tumor-immune interactions, translating those discoveries into therapeutics that reinvigorate antitumor immunity and alter survival and quality-of-life considerations for many patients.

This introduction frames the clinical, operational, and commercial dimensions that stakeholders must weigh when evaluating immune checkpoint inhibitor programs. Clinically, integrating biomarker testing, refining patient selection, and optimizing sequencing with chemotherapy and targeted agents remain primary considerations for therapeutic teams. Operationally, the complexity of introducing biologic therapies influences distribution choices, cold-chain logistics, and infusion capacity planning across hospitals and ambulatory settings. Commercially, alignment with payers, evidence generation to support reimbursement, and differentiated positioning based on mechanism of action and line of therapy are central to adoption strategies.

As you read further, the analysis that follows synthesizes clinical progress, regulatory posture, and system-level pressures to present a balanced view of opportunities and risks. The goal is to equip decision-makers with a clear, concise foundation for prioritizing investments and partnerships that will accelerate meaningful patient impact.

Identifying transformative shifts reshaping lung cancer immunotherapy including biomarker-driven care, combination approaches, and regulatory and payer dynamics

The landscape for lung cancer immunotherapy is in the midst of several concurrent and reinforcing shifts that are changing how therapies are developed, evaluated, and delivered. First, clinical practice has moved toward precision immuno-oncology where biomarker-driven selection-such as PD-L1 expression and broader genomic signatures-informs therapeutic choice and trial enrollment. Consequently, trial designs increasingly embed adaptive cohorts and biomarker-enriched arms to improve signal detection and expedite regulatory decision-making.

Second, combination strategies are now a core development focus, pairing checkpoint inhibitors with chemotherapy, targeted agents, or other immune modulators to address resistance mechanisms and enhance response durability. These combinations require new safety management paradigms and novel clinical endpoints, which in turn influence regulatory engagement and payer evidence expectations. Third, regulatory agencies and payers are placing greater emphasis on real-world evidence and health-economic outcomes, prompting sponsors to invest in longitudinal data collection and outcomes research alongside classical randomized trials.

Fourth, manufacturing and supply chain considerations are driving investment in scalable biologics production and cold-chain logistics. At the same time, digital health tools and decentralized trial methodologies are improving patient access and retention, expanding the potential study population beyond traditional academic centers. Taken together, these shifts are creating an environment where agility in clinical strategy, data generation, and stakeholder engagement will determine which therapies achieve broad adoption and meaningful patient benefit.

Assessing the cumulative impact of new United States tariff policies in 2025 on lung cancer immunotherapy supply chains, clinical programs, and commercial access

Policy actions that affect cross-border trade can reverberate across the drug development and commercialization ecosystem, and proposed tariff changes in 2025 present a complex set of operational and economic considerations for immune checkpoint inhibitor programs. Higher duties on imported biologic materials, specialized reagents, or finished products can increase the unit cost of goods, potentially pressuring manufacturers to reevaluate sourcing strategies and contract manufacturing relationships. In response, sponsors may accelerate localization of supply chains, renegotiate long-term supplier agreements, or diversify suppliers to mitigate single-source risks.

Clinical development is sensitive to supply interruptions and cost volatility. Tariff-driven increases in the cost of clinical supplies or delays at customs can complicate trial logistics, particularly for multicenter studies that rely on synchronized drug shipments. Sponsors can mitigate this risk by building buffer inventories, qualifying multiple depots, and leveraging regional manufacturing hubs where feasible. Meanwhile, commercial access strategies may need to adapt as payers scrutinize price increases; transparent communication about cost drivers and evidence of clinical value will be critical to maintaining formulary positions.

Finally, the policy environment can incentivize strategic partnerships and vertical integration, encouraging companies to explore regional production or licensing arrangements that preserve margins and secure supply. While tariffs add a layer of complexity, proactive operational planning, scenario-based financial modeling, and early engagement with regulatory and customs authorities can reduce disruption and preserve patient access to critical immunotherapies.

Decoding segmentation-driven insights across cancer type, distribution channel, treatment regimen, mechanism, line of therapy, and end user to optimize positioning

A fine-grained understanding of segmentation is essential for tailoring development and commercialization approaches across the heterogeneous lung cancer landscape. When considering cancer type, distinctions between Non-Small Cell Lung Cancer and Small Cell Lung Cancer drive different clinical trial designs, regulatory endpoints, and prescribing patterns, while within Non-Small Cell Lung Cancer the split between Non-Squamous and Squamous histologies shapes expected responses and safety profiles. Further subclassification such as Adenocarcinoma and Large Cell Carcinoma under Non-Squamous informs biomarker prevalence and the likely interaction with targeted therapies.

Distribution channel choices-from hospital pharmacy to online pharmacy, retail pharmacy, and specialty pharmacy-determine the logistics model, patient support structures, and reimbursement pathways. The treatment regimen axis separates monotherapy from combination therapy, and when combinations include chemotherapy or targeted therapy the clinical development strategy must address additive toxicities and regimen sequencing. End user segmentation across ambulatory surgical centers, home care settings, hospitals, and oncology clinics influences site readiness, infusion capacity, and the design of patient navigation services.

Mechanism of action segmentation differentiates CTLA-4 inhibitors from PD-1 and PD-L1 inhibitors, with specific agents such as ipilimumab, cemiplimab, nivolumab, pembrolizumab, atezolizumab, and durvalumab offering distinct clinical profiles that matter for labeling and positioning. Finally, line-of-therapy distinctions between first line, second line, and third or later determine the competitive set and the evidence bar required to displace incumbents. Integrating these segmentation dimensions allows sponsors to prioritize clinical programs, channel strategies, and evidence generation to match the needs of distinct patient populations and care settings.

Regional priorities and differentiated adoption trajectories across Americas, Europe, Middle East & Africa, and Asia-Pacific that influence access and commercialization

Regional variation in clinical practice, regulatory approach, and healthcare infrastructure materially affects how immune checkpoint inhibitors are adopted and scaled. In the Americas, established reimbursement pathways, strong oncology networks, and high clinical trial capacity support rapid uptake of novel regimens, though cost containment and payer scrutiny of value remain constant considerations. Market access strategies in this region often combine robust phase III evidence with real-world outcomes to secure formulary placement and favorable utilization policies.

In Europe, Middle East & Africa, heterogeneity in regulatory frameworks and payer models requires a nuanced approach that accounts for national health technology assessment processes, variable reimbursement timelines, and differing logistical capacities. Engagement with regional health authorities and local stakeholders is essential to align clinical evidence packages with country-specific value frameworks. In Asia-Pacific, the diversity of health systems spans advanced markets with accelerated adoption to emerging markets where access constraints and infrastructure gaps necessitate adaptive distribution and patient support programs. Manufacturing localization and strategic partnerships can be especially impactful in this region to improve affordability and supply reliability.

Across all regions, tailoring evidence generation to local decision drivers, investing in clinician education, and designing flexible distribution models are core imperatives. Cross-regional coordination can unlock efficiencies in global development while allowing targeted adaptations for local regulatory and payer landscapes.

Competitive and collaborative company-level insights revealing where innovation, partnerships, and portfolio strategies will determine leadership in lung cancer immunotherapy

Company strategies in lung cancer immunotherapy are converging around several themes: differentiated clinical positioning, strategic alliances, portfolio breadth, and capabilities in evidence generation. Firms that prioritize robust biomarker programs and companion diagnostic partnerships position themselves to capture clinically defined subpopulations where therapeutic benefit is most pronounced. Companies that invest in combination science and manage early safety signals effectively can create compelling differentiation versus monotherapy options.

Strategic collaborations-ranging from research partnerships with biotechnology innovators to co-development agreements with makers of targeted agents-accelerate access to complementary mechanisms and expand clinical options for resistant disease. Firms that build integrated capabilities in real-world evidence generation, health economics, and outcomes research strengthen payer discussions and facilitate reimbursement negotiations. Meanwhile, investments in scalable biologics manufacturing and geographically diversified supply chains reduce operational risk and can support more predictable commercialization rollouts.

Competitive positioning also rests on commercial execution, with leaders offering comprehensive patient support programs, education for treating physicians, and adaptive pricing strategies that reflect value-based outcomes. Companies that combine strong clinical data with operational excellence and payor-aligned value propositions will be best placed to sustain adoption and long-term utilization across diverse care settings.

Actionable recommendations for industry leaders to accelerate development, enhance access, and build resilient commercial and clinical pathways in immunotherapy

Industry leaders can accelerate progress and de-risk commercialization by pursuing a set of actionable, prioritized initiatives. First, align R&D portfolios with biomarker-defined indications and develop companion diagnostic strategies early to streamline regulatory pathways and improve patient selection. Concurrently, design combination trials that incorporate adaptive elements and meaningful patient-centric endpoints to demonstrate value beyond traditional survival metrics. Second, invest in decentralized and hybrid trial models to broaden recruitment, enhance retention, and generate more representative real-world evidence that supports payer dialogues.

Third, fortify supply chains through supplier diversification, regional manufacturing options, and inventory strategies that reduce exposure to trade disruptions and policy shocks. Fourth, engage payers proactively with transparent value dossiers and outcomes-based contracting where appropriate to address affordability concerns while protecting access. Fifth, build differentiated patient support programs that facilitate adherence, manage immune-related adverse events, and enable treatment continuity across hospitals, oncology clinics, home care settings, and specialty pharmacies.

Finally, cultivate strategic partnerships with diagnostics firms, academic centers, and contract research organizations to accelerate translational science and speed clinical development. By implementing these recommendations, leaders will enhance the likelihood of successful product launches, sustainable access, and measurable improvements in patient outcomes.

Robust research methodology detailing evidence sources, expert engagement, triangulation methods, and limitations used to produce defensible market intelligence

The analysis underpinning this report integrates multiple evidence streams to ensure rigorous, defensible conclusions. Secondary research included peer-reviewed clinical literature, regulatory guidance documents, and publicly available clinical trial registries to map therapeutic mechanisms, safety profiles, and trial designs. To complement these sources, structured interviews were conducted with oncologists, clinical trial investigators, health economics specialists, regulatory affairs experts, and supply chain leaders to capture experiential insights and operational challenges.

Data triangulation methods linked qualitative interview findings with published evidence to validate emergent themes and identify gaps in the public record. Segmentation analyses were applied to clinical, distribution, and end-user dimensions to illuminate differentiated adoption pathways. Limitations of the methodology include the rapidly evolving nature of clinical data, regional variability in regulatory timelines, and the potential for emerging trial results to alter competitive dynamics; to mitigate these, the study highlights areas for ongoing surveillance and recommends periodic updates to maintain relevance.

Where appropriate, the methodology prioritized transparency in source selection and analytic assumptions, enabling stakeholders to assess the provenance of key findings and to adapt the approach for bespoke analyses focused on particular geographies, mechanisms, or therapeutic combinations.

Concluding synthesis that crystallizes strategic implications from clinical innovation, policy shifts, and operational priorities for lung cancer immunotherapy stakeholders

The convergence of scientific innovation, strategic commercialization tactics, and policy evolution is reshaping how immune checkpoint inhibitors are developed and used in lung cancer care. Clinically, biomarker-driven selection and combination regimens are refining therapeutic benefit while introducing new complexities for safety management and trial design. Operationally, distribution channel choice and end-user readiness influence access, and resilient supply chains are essential to preserve continuity of care in the face of policy shocks.

From a strategic perspective, companies that integrate diagnostic strategies, invest in robust real-world evidence programs, and engage payers proactively will be better positioned to achieve durable adoption. Regional differentiation requires tailored evidence packages and localized execution plans to accommodate varying regulatory and reimbursement landscapes. Collectively, these insights underscore that success in this therapeutic area hinges on coordinated efforts across clinical development, evidence generation, manufacturing, and payer engagement.

In closing, the evolving immunotherapy landscape presents substantial opportunities to improve patient outcomes, but realizing those gains requires disciplined strategy, operational resilience, and sustained collaboration among industry, clinicians, and health systems.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. FDA approval and clinical impact of adjuvant PD-1 inhibitors in early-stage NSCLC management
• 5.2. Real-world evidence studies highlighting safety profiles of checkpoint inhibitors in elderly lung cancer cohorts
• 5.3. Development of next-generation bispecific antibodies targeting PD-L1 and LAG-3 in metastatic lung tumors
• 5.4. Integration of liquid biopsy biomarkers to predict response to immune checkpoint blockade in NSCLC patients
• 5.5. Emergence of cost-effectiveness models assessing long-term survival benefits of PD-1/PD-L1 therapies in lung cancer
• 5.6. Expanding indications for durvalumab consolidation therapy following chemoradiation in stage III unresectable NSCLC

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Immune Checkpoint Inhibitors for Lung Cancer Market, by Cancer Type

• 8.1. Cancer Type
  • 8.1.1. Non-Small Cell Lung Cancer
    • 8.1.1.1. Non-Squamous
    • 8.1.1.1.1. Adenocarcinoma
    • 8.1.1.1.2. Large Cell Carcinoma
    • 8.1.1.2. Squamous
  • 8.1.2. Small Cell Lung Cancer

9. Immune Checkpoint Inhibitors for Lung Cancer Market, by Distribution Channel

• 9.1. Hospital Pharmacy
• 9.2. Online Pharmacy
• 9.3. Retail Pharmacy
• 9.4. Specialty Pharmacy

10. Immune Checkpoint Inhibitors for Lung Cancer Market, by Treatment Regimen

• 10.1. Combination Therapy
  • 10.1.1. With Chemotherapy
  • 10.1.2. With Targeted Therapy
• 10.2. Monotherapy

11. Immune Checkpoint Inhibitors for Lung Cancer Market, by End User

• 11.1. Ambulatory Surgical Centers
• 11.2. Home Care Settings
• 11.3. Hospitals
• 11.4. Oncology Clinics

12. Immune Checkpoint Inhibitors for Lung Cancer Market, by Mechanism Of Action

• 12.1. CTLA-4 Inhibitor
  • 12.1.1. Ipilimumab
• 12.2. PD-1 Inhibitor
  • 12.2.1. Cemiplimab
  • 12.2.2. Nivolumab
  • 12.2.3. Pembrolizumab
• 12.3. PD-L1 Inhibitor
  • 12.3.1. Atezolizumab
  • 12.3.2. Durvalumab

13. Immune Checkpoint Inhibitors for Lung Cancer Market, by Line Of Therapy

• 13.1. First Line
• 13.2. Second Line
• 13.3. Third Or Later

14. Immune Checkpoint Inhibitors for Lung Cancer Market, by Region

• 14.1. Americas
  • 14.1.1. North America
  • 14.1.2. Latin America
• 14.2. Europe, Middle East & Africa
  • 14.2.1. Europe
  • 14.2.2. Middle East
  • 14.2.3. Africa
• 14.3. Asia-Pacific

15. Immune Checkpoint Inhibitors for Lung Cancer Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Immune Checkpoint Inhibitors for Lung Cancer Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Share Analysis, 2024
• 17.2. FPNV Positioning Matrix, 2024
• 17.3. Competitive Analysis
  • 17.3.1. Merck & Co., Inc.
  • 17.3.2. Bristol-Myers Squibb Company
  • 17.3.3. F. Hoffmann-La Roche Ltd
  • 17.3.4. AstraZeneca PLC
  • 17.3.5. Regeneron Pharmaceuticals, Inc.
  • 17.3.6. Pfizer Inc.
  • 17.3.7. BeiGene, Ltd.
  • 17.3.8. Innovent Biologics, Inc.
  • 17.3.9. Shanghai Junshi Biosciences Co., Ltd.
  • 17.3.10. Sanofi S.A.

LIST OF FIGURES

• FIGURE 1. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2032 (%)
• FIGURE 13. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 30. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 31. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 32. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ADENOCARCINOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ADENOCARCINOMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ADENOCARCINOMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ADENOCARCINOMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ADENOCARCINOMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ADENOCARCINOMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LARGE CELL CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LARGE CELL CARCINOMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LARGE CELL CARCINOMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LARGE CELL CARCINOMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LARGE CELL CARCINOMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LARGE CELL CARCINOMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SQUAMOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SQUAMOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SQUAMOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SQUAMOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SQUAMOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SQUAMOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SMALL CELL LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SMALL CELL LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SMALL CELL LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SPECIALTY PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SPECIALTY PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SPECIALTY PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SPECIALTY PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONCOLOGY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONCOLOGY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONCOLOGY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONCOLOGY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY IPILIMUMAB, BY REGION, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY IPILIMUMAB, BY REGION, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY IPILIMUMAB, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY IPILIMUMAB, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY IPILIMUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY IPILIMUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CEMIPLIMAB, BY REGION, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CEMIPLIMAB, BY REGION, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CEMIPLIMAB, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CEMIPLIMAB, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CEMIPLIMAB, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CEMIPLIMAB, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NIVOLUMAB, BY REGION, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NIVOLUMAB, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NIVOLUMAB, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NIVOLUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NIVOLUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PEMBROLIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PEMBROLIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PEMBROLIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PEMBROLIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITOR, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITOR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITOR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITOR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITOR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITOR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ATEZOLIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ATEZOLIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ATEZOLIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ATEZOLIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DURVALUMAB, BY REGION, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DURVALUMAB, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DURVALUMAB, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DURVALUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DURVALUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 203. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 204. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 205. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 206. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 207. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 208. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SECOND LINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 209. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 210. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 211. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY THIRD OR LATER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 212. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY THIRD OR LATER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 213. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY THIRD OR LATER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 214. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY THIRD OR LATER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 215. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY THIRD OR LATER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 216. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY THIRD OR LATER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 217. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 218. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 219. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 220. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 221. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 222. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 223. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 224. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 225. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
• TABLE 226. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2025-2032 (USD MILLION)
• TABLE 227. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2024 (USD MILLION)
• TABLE 228. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2025-2032 (USD MILLION)
• TABLE 229. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 230. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 231. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
• TABLE 232. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
• TABLE 233. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
• TABLE 234. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
• TABLE 235. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 236. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 237. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
• TABLE 238. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
• TABLE 239. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, 2018-2024 (USD MILLION)
• TABLE 240. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, 2025-2032 (USD MILLION)
• TABLE 241. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2024 (USD MILLION)
• TABLE 242. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2025-2032 (USD MILLION)
• TABLE 243. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2024 (USD MILLION)
• TABLE 244. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITOR, 2025-2032 (USD MILLION)
• TABLE 245. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
• TABLE 246. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
• TABLE 247. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 248. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 249. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 250. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 251. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 252. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 253. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
• TABLE 254. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2025-2032 (USD MILLION)
• TABLE 255. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2024 (USD MILLION)
• TABLE 256. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2025-2032 (USD MILLION)
• TABLE 257. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 258. NORTH AMERICA IMMU